GAITHERSBURG, Md. & PARIS--(BUSINESS WIRE)--MedImmune, the global biologics business of AstraZeneca, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), today announced a three-year strategic collaboration to advance research across a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. Research will explore translational biology and new disease mechanisms, as well as evaluate potential drug candidates.
